Search by Drug Name or NDC
NDC 49702-0208-53 LEXIVA 50 mg/mL Details
LEXIVA 50 mg/mL
LEXIVA is a ORAL SUSPENSION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by ViiV Healthcare Company. The primary component is FOSAMPRENAVIR CALCIUM.
MedlinePlus Drug Summary
Fosamprenavir is used along with other medications to treat human immunodeficiency virus (HIV) infection. Fosamprenavir is in a class of medications called protease inhibitors. It works by decreasing the amount of HIV in the blood. Although fosamprenavir does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other life-style changes may decrease the risk of transmitting the HIV virus to other people.
Related Packages: 49702-0208-53Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Fosamprenavir
Product Information
| NDC | 49702-0208 |
|---|---|
| Product ID | 49702-208_93fd2788-9ab5-4d86-b9e0-88a10e5de332 |
| Associated GPIs | 12104525101820 |
| GCN Sequence Number | 058365 |
| GCN Sequence Number Description | fosamprenavir calcium ORAL SUSP 50 MG/ML ORAL |
| HIC3 | W5C |
| HIC3 Description | ANTIVIRALS, HIV-SPECIFIC, PROTEASE INHIBITORS |
| GCN | 23783 |
| HICL Sequence Number | 025662 |
| HICL Sequence Number Description | FOSAMPRENAVIR CALCIUM |
| Brand/Generic | Brand |
| Proprietary Name | LEXIVA |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | fosamprenavir calcium |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | SUSPENSION |
| Route | ORAL |
| Active Ingredient Strength | 50 |
| Active Ingredient Units | mg/mL |
| Substance Name | FOSAMPRENAVIR CALCIUM |
| Labeler Name | ViiV Healthcare Company |
| Pharmaceutical Class | Cytochrome P450 3A4 Inducers [MoA], Cytochrome P450 3A4 Inhibitors [MoA], HIV Protease Inhibitors [MoA], P-Glycoprotein Inducers [MoA], Protease Inhibitor [EPC] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA022116 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 49702-0208-53 (49702020853)
| NDC Package Code | 49702-208-53 |
|---|---|
| Billing NDC | 49702020853 |
| Package | 225 mL in 1 BOTTLE (49702-208-53) |
| Marketing Start Date | 2010-10-04 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |